Conversely, downregulation of ANX2 expression has been reported in prostate cancer (Chetcuti et al, 2001; Banerjee et al, 2003; Liu et al, 2003), osteosarcoma (Gillette et al, 2004), oesophageal squamous cell carcinoma (SCC) (Zhi et al, 2003) and head and neck SCC (Pena-Alonso et al, 2008). Here, ANXA2 is linked to Familial prostate cancer.